Bone marrow scintigraphy in the diagnosis of bone metastasis in prostate cancer

1994 ◽  
Vol 26 (1) ◽  
pp. 53-61
Author(s):  
H. Fuse ◽  
O. Nagakawa ◽  
H. Seto ◽  
T. Katayama
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Bone Metastasis ◽  
Bone Marrow Scintigraphy ◽  
Diagnosis Of Bone Metastasis

scholarly journals Long non‐coding RNA NORAD promotes the prostate cancer cell extracellular vesicle release via microRNA-541-3p-regulated PKM2 to induce bone metastasis of prostate cancer

2021 ◽  
Vol 40 (1) ◽  
Author(s):  
Chuan-yi Hu ◽  
Juan Chen ◽  
Xin-hua Qin ◽  
Pan You ◽  
Jie Ma ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Bone Metastasis ◽  
Stromal Cells ◽  
Bone Marrow Stromal Cells ◽  
Marrow Stromal Cells ◽  
Downstream Target ◽  
Non Coding Rna ◽  
Target Molecules ◽  
Long Non Coding Rna

Abstract Background Bone metastasis is the leading cause of mortality and reduced quality of life in patients with metastatic prostate cancer (PCa). Long non-coding RNA activated by DNA damage (NORAD) has been observed to have an abnormal expression in various cancers. This article aimed to explore the molecular mechanism underlying the regulatory role of NORAD in bone metastasis of PCa. Methods NORAD expression in clinical PCa tissues and cell lines was detected with the application of qRT-PCR. Cancer cells were then transfected with plasmids expressing NORAD, after which Transwell assay and CCK-8 assay were carried out to detect proliferation, migration, and bone metastasis of PCa. NORAD downstream target molecules were screened through bioinformatics analysis, followed by further verification using dual luciferase assay. Extracellular vesicles (EVs) were labeled with PKH67 and interacted with bone marrow stromal cells. The gain- and loss-function method was applied to determine the internalization and secretion of PCa cells-derived EVs under the intervention of downstream target molecules or NORAD. Results PCa tissues and cell lines were observed to have a high expression of NORAD, particularly in tissues with bone metastasis. NORAD knockdown resulted in reduced secretion and internalization of EVs, and suppressed proliferation, migration, and bone metastasis of PCa cells. It was indicated that NORAD interacted with miR-541-3p, leading to the upregulation of PKM2. Forced expression of PKM2 promoted the transfer of PKH67-labeled EVs to bone marrow stromal cells. Conclusions NORAD might serve as a ceRNA of miR-541-3p to promote PKM2 expression, thereby enhancing the development of bone metastasis in PCa by promoting internalization and transfer of EVs of cancer cells, providing an insight into a novel treatment for the disorder.

scholarly journals Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis

Molecules ◽  
2020 ◽  
Vol 25 (10) ◽  
pp. 2380 ◽  
Author(s):  
Shian-Ren Lin ◽  
Ntlotlang Mokgautsi ◽  
Yen-Nien Liu
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Bone Metastasis ◽  
Signaling Pathways ◽  
Late Stage ◽  
Ras Signaling ◽  
Cancer Death ◽  
Metastatic Site ◽  
Cancer Types ◽  
Cytological Changes

Prostate cancer (PCa) is one of the most prevalent and malignant cancer types in men, which causes more than three-hundred thousand cancer death each year. At late stage of PCa progression, bone marrow is the most often metastatic site that constitutes almost 70% of metastatic cases of the PCa population. However, the characteristic for the osteo-philic property of PCa is still puzzling. Recent studies reported that the Wnt and Ras signaling pathways are pivotal in bone metastasis and that take parts in different cytological changes, but their crosstalk is not well studied. In this review, we focused on interactions between the Wnt and Ras signaling pathways during each stage of bone metastasis and present the fate of those interactions. This review contributes insights that can guide other researchers by unveiling more details with regard to bone metastasis and might also help in finding potential therapeutic regimens for preventing PCa bone metastasis.

Radium 223 treatment in metastatic castrate-resistant prostate cancer: Impact of sequencing on survival—Real-world outcomes from a single United Kingdom center.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 223-223 ◽  
Author(s):  
Xue Yan Jiang ◽  
Sarah Atkinson ◽  
Sam Cuming ◽  
Alexander Burns ◽  
Rachel Anne Pearson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Bone Metastasis ◽  
Systemic Treatment ◽  
Survival Outcomes ◽  
Prior Chemotherapy ◽  
Radium 223 ◽  
Castrate Resistant Prostate Cancer ◽  
Castrate Resistant ◽  
The Impact

223 Background: Radium 223 (Ra-223) is a FDA and EMA approved alpha particle radiopharmaceutical used to treat men with metastatic castrate resistant prostate cancer (mCRPC) with symptomatic bone metastasis. In view of emerging systemic options, new EMA 2018 licence indication is for 3rd line onwards. We aim to evaluate the impact of systemic therapy sequencing on survival outcomes from a heterogeneous cohort of 228 patients treated with Ra-223 in a single UK centre. Methods: We prospectively collected data from 228 men underwent Ra-223 therapy for mCRPC between April 2014 and August 2018. Survival outcomes in relation to sequence of systemic treatment used prior to Ra-223 were analysed. Results: Medium age = 72 (51-87) years. Most patients (n = 142, 69%) received at least one systemic agent prior to Ra-223: docetaxel and/or cabaxitaxel chemotherapy (n = 60, 29%), abiraterone (n = 62, 30.1%) and enzalutamide (n = 67, 32.5%) in various sequences. No patients received concurrent Ra-223 /systemic treatment other than LHRH analogue. Key findings are summarized in table below. Conclusions: Our data demonstrated better survival trend in patients who received Ra-223 early. Patients who received prior chemotherapy have worse survival compared with those who were chemo-naïve likely due to bone marrow depletion. Ra-223 should not be offered to patients who have already had both cabaxitaxel and docetaxel as their medium survival is too poor to justify a treatment which takes 6 months to complete.[Table: see text]

scholarly journals Therapeutic Potential of Adult Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis

2009 ◽  
Vol 15 (23) ◽  
pp. 7175-7185 ◽  
Author(s):  
D. Chanda ◽  
T. Isayeva ◽  
S. Kumar ◽  
J. A. Hensel ◽  
A. Sawant ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Bone Metastasis ◽  
Therapeutic Potential ◽  
Adult Bone Marrow ◽  
Adult Bone

scholarly journals Comparison of PET/CT and MRI in the Diagnosis of Bone Metastasis in Prostate Cancer Patients: A Network Analysis of Diagnostic Studies

2021 ◽  
Vol 11 ◽  
Author(s):  
Fanxiao Liu ◽  
Jinlei Dong ◽  
Yelong Shen ◽  
Canhua Yun ◽  
Ruixiao Wang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Metastasis ◽  
Cancer Patients ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
High Quality ◽  
Psma Pet ◽  
Pet Ct ◽  
3.0 T ◽  
Diagnosis Of Bone Metastasis

BackgroundAccurate diagnosis of bone metastasis status of prostate cancer (PCa) is becoming increasingly more important in guiding local and systemic treatment. Positron emission tomography/computed tomography (PET/CT) and magnetic resonance imaging (MRI) have increasingly been utilized globally to assess the bone metastases in PCa. Our meta-analysis was a high-volume series in which the utility of PET/CT with different radioligands was compared to MRI with different parameters in this setting.Materials and MethodsThree databases, including Medline, Embase, and Cochrane Library, were searched to retrieve original trials from their inception to August 31, 2019 according to the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement. The methodological quality of the included studies was assessed by two independent investigators utilizing Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2). A Bayesian network meta-analysis was performed using an arm-based model. Absolute sensitivity and specificity, relative sensitivity and specificity, diagnostic odds ratio (DOR), and superiority index, and their associated 95% confidence intervals (CI) were used to assess the diagnostic value.ResultsForty-five studies with 2,843 patients and 4,263 lesions were identified. Network meta-analysis reveals that 68Ga-labeled prostate membrane antigen (68Ga-PSMA) PET/CT has the highest superiority index (7.30) with the sensitivity of 0.91 and specificity of 0.99, followed by 18F-NaF, 11C-choline, 18F-choline, 18F-fludeoxyglucose (FDG), and 18F-fluciclovine PET/CT. The use of high magnetic field strength, multisequence, diffusion-weighted imaging (DWI), and more imaging planes will increase the diagnostic value of MRI for the detection of bone metastasis in prostate cancer patients. Where available, 3.0-T high-quality MRI approaches 68Ga-PSMA PET/CT was performed in the detection of bone metastasis on patient-based level (sensitivity, 0.94 vs. 0.91; specificity, 0.94 vs. 0.96; superiority index, 4.43 vs. 4.56).Conclusions68Ga-PSMA PET/CT is recommended for the diagnosis of bone metastasis in prostate cancer patients. Where available, 3.0-T high-quality MRI approaches 68Ga-PSMA PET/CT should be performed in the detection of bone metastasis.

The usefulness of bone-marrow scintigraphy in the detection of bone metastasis from prostatic cancer

1985 ◽  
Vol 11 (8) ◽  
pp. 319-322 ◽  
Author(s):  
Nobuaki Otsuka ◽  
Masao Fukunaga ◽  
Teruki Sone ◽  
Masaya Yoneda ◽  
Noriaki Saito ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Metastasis ◽  
Prostatic Cancer ◽  
Bone Marrow Scintigraphy

A Case of Synovial Sarcoma with Bone Metastasis Identified by Bone Marrow Scintigraphy

1985 ◽  
Vol 10 (4) ◽  
pp. 260-263 ◽  
Author(s):  
NOBUAKI OTSUKA ◽  
RIKUSHI MORITA ◽  
TAKASHI YAMAMOTO ◽  
AKIRA MURANAKA ◽  
TATSUSHI TOMOMITSU ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Metastasis ◽  
Synovial Sarcoma ◽  
Bone Marrow Scintigraphy

The Advantage of a Combined SPECT/CT in the Diagnosis of Bone Metastases

2017 ◽  
Vol 62 (5) ◽  
pp. 33-39 ◽  
Author(s):  
А. РЫжков ◽  
A. RYzhkov ◽  
А. Крылов ◽  
A. Krylov ◽  
С. Ширяев ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prostate Cancer ◽  
Bone Metastasis ◽  
Bone Metastases ◽  
Multiple Metastases ◽  
Cancer Prostate ◽  
Diagnostic Capabilities ◽  
Diagnosis Of Bone Metastasis

Purpose: To define the diagnostic capabilities of SPECT/CT in comparison with WBS in patients with bone metastases. Material and methods: It was included 67 patients with bone metastases of breast cancer, prostate cancer and other tumors. The evaluation was included WBS and SPECT/CT. Results: All patients were divided into 2 groups: with single and multiple metastases. SPECT/CT showed higher efficiency in detecting bone metastases than WBS. The full detection of bone metastases with WBS ranged from 31 to 56 % compared to SPECT/CT for groups respectively. In some cases (for groups respectively 4 % to 9.5 % depending on the number of metastases and their localization) of WBS was not informative, recorded the absence of lesions. Conclusion: SPECT/CT can improve the diagnosis of bone metastasis.

Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression

The Prostate ◽  
2013 ◽  
Vol 73 (16) ◽  
pp. 1738-1746 ◽  
Author(s):  
Estelle Ricci ◽  
Eve Mattei ◽  
Charles Dumontet ◽  
Colby L. Eaton ◽  
Freddy Hamdy ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Bone Marrow ◽  
Stem Cell ◽  
Bone Metastasis ◽  
Cancer Stem Cell ◽  
Cancer Patients ◽  
Stem Cell Markers ◽  
Cell Markers ◽  
Cancer Stem Cell Markers
Sign in / Sign up

Export Citation Format

Share Document